Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: Amonocenter observational study with clinical and JC virus load monitoring
Autore:
Gasnault, J; Kousignian, P; Kahraman, M; Rahoiljaon, J; Matheron, S; Delfraissy, JF; Taoufik, Y;
Indirizzi:
Hop Bicetre, Dept Internal Med, Neuro AIDS Rehabil Unit, Le Kremlin Bicetre, France Hop Bicetre Le Kremlin Bicetre France Unit, Le Kremlin Bicetre, France Hop Bicetre, Immunol Lab, Le Kremlin Bicetre, France Hop Bicetre Le Kremlin Bicetre France l Lab, Le Kremlin Bicetre, France Fac Med Paris Sud, INSERM E109, Le Kremlin Bicetre, France Fac Med Paris Sud Le Kremlin Bicetre France Le Kremlin Bicetre, France Hop Bichat, Dept Infect Dis, F-75877 Paris, France Hop Bichat Paris France F-75877 , Dept Infect Dis, F-75877 Paris, France
Titolo Testata:
JOURNAL OF NEUROVIROLOGY
fascicolo: 4, volume: 7, anno: 2001,
pagine: 375 - 381
SICI:
1355-0284(200108)7:4<375:CIAPML>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVE ANTIRETROVIRAL THERAPY; CEREBROSPINAL-FLUID; SURVIVAL; IMPROVEMENT; SCALE; HAART; HIV; ERA;
Keywords:
HIV; AIDS; anti-retroviral therapy; JC virus; progressive multifocal leukoencephalopathy; cidofovir;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Gasnault, J Hop Univ Bicetre, USR, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France Hop Univ Bicetre 78 Rue Gen Leclerc Le Kremlin Bicetre France F-94275
Citazione:
J. Gasnault et al., "Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: Amonocenter observational study with clinical and JC virus load monitoring", J NEUROVIRO, 7(4), 2001, pp. 375-381

Abstract

A monocenter observational study was conducted to determine the clinical and virological effects of cidofovir added to highly active anti-retroviral therapy (HAART) in AIDS-associated progressive multifocal leukoencephalopathy (PML). Exposure to other anti-viral drugs or late initiation of cidofovir were exclusion criteria. Of the 53 consecutive patients with virologically proven PML admitted at the NeuroAIDS Unit of Bicetre Hospital between May1996 and July 2000 and having received HAART with or without cidofovir, 46met the inclusion criteria. Cidofovir was initiated in most cases on compassionate grounds. The 22 patients treated with HAART only (HAART group) were compared to the 24 patients treated with HAART and cidofovir (CDV group). Survival, neurological outcome assessed by the expanded disability status scale (EDSS), and monitoring of the JC virus (JCV) load in CSF were investigated prospectively. At baseline (date of initiation or intensification of HAART), both groups were similar regarding CD4 cell count, plasma HIV load,CSF JCV load, EDSS, and demographic features. Both groups had similar response to HAART in terms of plasma HIV load and CD4 cell count. At month 6, CSF-JCV load was below the detection level in 8 out of 24 (33%) patients from the CDV group and 7 out of 18 (39%) patients from the HAART group (P = 0.71). One-year cumulative probability of being alive was 62% in the CDV group and 53% in the HAART group (P = 0.72). However, an additional benefit with respect to survival was observed in patients who were given cidofovir after adjustment to the following baseline variables (CSF-JCV load, CD4 cell count, and EDSS). Despite the addition of cidofovir to HAART, no significantbenefit had been observed in neurological outcome, particularly in patients with an early worsening.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 17:26:10